OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
228670$7250.0060

Ray Co Ltd

Advanced Medical Equipment & TechnologyVerified

Ray Co Ltd has a market capitalization of 113,114,862,500 KRW and a price-to-earnings ratio of 36.05, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 1.48, suggesting that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 1.24, which is slightly above 1, indicating that it has enough current assets to cover its current liabilities, but not by a large margin. In terms of profitability, Ray Co Ltd has a return on equity (ROE) of 4.1%, which is relatively low, and a return on assets (ROA) of 1.63%, also indicating suboptimal asset utilization. The company's operating income is negative at -21,052,369,630 KRW, which is a significant concern, as it suggests that the company is not generating enough revenue to cover its operating expenses. The gross profit margin is 47.4%, which is a positive sign, but the negative operating income indicates inefficiencies in cost management. Ray Co Ltd operates through two segments: Digital Therapy Solutions and Digital Diagnostic Systems. The company's revenue is derived from both domestic and overseas markets, but the input data does not provide specific revenue concentration figures for each segment or region. The lack of detailed segment and geographic revenue data limits the ability to assess the company's exposure to specific markets or products. The company's growth trajectory is mixed. The financial snapshot does not provide historical revenue data to assess year-over-year growth, but the negative operating income and the current liquidity position suggest that the company may be facing challenges in sustaining growth. The company's free cash flow is positive at 6,045,071,500 KRW, which is a positive sign, but the capital expenditure of -3,621,906,480 KRW indicates that the company is investing in its operations. The risk assessment for Ray Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 1.05, which is relatively high, and the key flag of negative net cash after subtracting total debt suggests that the company may face liquidity challenges. The company's risk profile is further complicated by the negative operating income, which could lead to increased financial stress. Recent events and filings for Ray Co Ltd are not detailed in the input data, but the company's financial performance and risk profile suggest that it may be facing operational and financial challenges. The company's negative operating income and high debt-to-equity ratio are red flags that may require further investigation. The company's liquidity position is also a concern, as the current ratio is only slightly above 1, indicating that the company may struggle to meet its short-term obligations.

30-day price · 228670+1870.00 (+35.6%)
Low$4795.00High$11690.00Close$7130.00As of12 May, 00:00 UTC
Profile
CompanyRay Co Ltd
Ticker228670.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Ray Co Ltd is a Korea-based company engaged in the manufacturing of dental medical device equipment, operating through two segments: Digital Therapy Solutions and Digital Diagnostic Systems, generating revenue from the sale of 3D form printers, pano imaging devices, and ceph imaging devices.

Classification. Ray Co Ltd is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92 based on verified market data.

Ray Co Ltd has a market capitalization of 113,114,862,500 KRW and a price-to-earnings ratio of 36.05, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 1.48, suggesting that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 1.24, which is slightly above 1, indicating that it has enough current assets to cover its current liabilities, but not by a large margin. In terms of profitability, Ray Co Ltd has a return on equity (ROE) of 4.1%, which is relatively low, and a return on assets (ROA) of 1.63%, also indicating suboptimal asset utilization. The company's operating income is negative at -21,052,369,630 KRW, which is a significant concern, as it suggests that the company is not generating enough revenue to cover its operating expenses. The gross profit margin is 47.4%, which is a positive sign, but the negative operating income indicates inefficiencies in cost management. Ray Co Ltd operates through two segments: Digital Therapy Solutions and Digital Diagnostic Systems. The company's revenue is derived from both domestic and overseas markets, but the input data does not provide specific revenue concentration figures for each segment or region. The lack of detailed segment and geographic revenue data limits the ability to assess the company's exposure to specific markets or products. The company's growth trajectory is mixed. The financial snapshot does not provide historical revenue data to assess year-over-year growth, but the negative operating income and the current liquidity position suggest that the company may be facing challenges in sustaining growth. The company's free cash flow is positive at 6,045,071,500 KRW, which is a positive sign, but the capital expenditure of -3,621,906,480 KRW indicates that the company is investing in its operations. The risk assessment for Ray Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 1.05, which is relatively high, and the key flag of negative net cash after subtracting total debt suggests that the company may face liquidity challenges. The company's risk profile is further complicated by the negative operating income, which could lead to increased financial stress. Recent events and filings for Ray Co Ltd are not detailed in the input data, but the company's financial performance and risk profile suggest that it may be facing operational and financial challenges. The company's negative operating income and high debt-to-equity ratio are red flags that may require further investigation. The company's liquidity position is also a concern, as the current ratio is only slightly above 1, indicating that the company may struggle to meet its short-term obligations.
Key takeaways
  • Ray Co Ltd has a high price-to-earnings ratio of 36.05, indicating a premium valuation relative to its earnings.
  • The company's return on equity is 4.1%, which is relatively low, and its return on assets is 1.63%, indicating suboptimal asset utilization.
  • Ray Co Ltd has a negative operating income of -21,052,369,630 KRW, which is a significant concern for its financial health.
  • The company's liquidity position is characterized by a current ratio of 1.24, which is slightly above 1, indicating that it has enough current assets to cover its current liabilities, but not by a large margin.
  • The company's debt-to-equity ratio is 1.05, which is relatively high, and the key flag of negative net cash after subtracting total debt suggests that the company may face liquidity challenges.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$111.32B
Gross profit$52.75B
Operating income-$21.05B
Net income$3.14B
R&D
SG&A
D&A
SBC
Operating cash flow$12.85B
CapEx-$3.62B
Free cash flow$6.05B
Total assets$192.24B
Total liabilities$115.74B
Total equity$76.50B
Cash & equivalents$28.33B
Long-term debt$80.66B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$7250.00
Market cap$113.11B
Enterprise value$165.45B
P/E36.0
Reported non-GAAP P/E
EV/Revenue1.5
EV/Op income
EV/OCF12.9
P/B1.5
P/Tangible book1.5
Tangible book$76.50B
Net cash-$52.33B
Current ratio1.2
Debt/Equity1.1
ROA1.6%
ROE4.1%
Cash conversion4.1%
CapEx/Revenue-3.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 160 companies
Metric228670Activity
Op margin-18.9%-24.0% medp25 -212.9% · p75 6.1%above median
Net margin2.8%-20.7% medp25 -188.5% · p75 4.8%above median
Gross margin47.4%49.8% medp25 36.6% · p75 67.4%below median
CapEx / revenue-3.2%-4.7% medp25 -11.2% · p75 -1.8%above median
Debt / equity105.0%3.6% medp25 0.0% · p75 22.2%top quartile
Observations
IR observations
Mean price target10,900.00 KRW
Median price target10,900.00 KRW
High price target12,500.00 KRW
Low price target9,300.00 KRW
Mean recommendation2.50 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate648.78 KRW
Last actual EPS201.00 KRW
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:02 UTC#5f63bf42
Market quoteclose KRW 7250.00 · shares 0.02B diluted
no public URL
2026-05-10 12:02 UTC#cbe4b5d0
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:05 UTCJob: 983e041e